Cutaneous T-Cell Lymphoma
Relapsed/Refractory
The term “relapsed” refers to disease that reappears or grows again after a period of remission. The term “refractory” is used to describe when the lymphoma does not respond to treatment (meaning that the cancer cells continue to grow) or when the response to treatment does not last very long.
Treatment options commonly used for relapsed/refractory CTCL include:
- Brentuximab vedotin (Adcetris)
- Gemcitabine (Gemzar)
- Mogamulizumab-kpkc (Poteligeo)
- Pralatexate (Folotyn)
- Romidepsin (Istodax)
- Vorinostat (Zolinza)
Learn More
To learn more about CTCL, view the T-Cell Lymphomas Guide. Want to talk to someone? For answers to lymphoma-related questions and resources, contact our Lymphoma Resource Center at (800) 500-9976 or [email protected].
Additional Resources
To learn more about CTCL, view the T-Cell Lymphomas Guide.
Events
Events
-
-
Educational Forum on Lymphoma
The Educational Forum on Lymphoma is a virtual two-day conference in the fall of every year that […]
-
Ask the Doctor About Lymphoma: Navigating Relapsed/Refractory Disease
This program will provide patients with information on what to consider if their lymphoma or […]
-
Ask the Doctor About Lymphoma: Navigating Relapsed/Refractory Disease
Ask the Doctor About Lymphoma is a virtual two-hour program that combines a comprehensive and […]